ReviewMini reviews in medicinal chemistry2026
Innovations in Biosensing Technologies for Cancer Diagnosis and Theranostics.
Review in Mini reviews in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a major global health concern that demands the development of novel strategies for early identification, accurate treatment, and continuous monitoring of therapeutic outcomes. The search for new approaches to cancer management has led to the emergence of an exciting multidisciplinary field that integrates biotechnology, medicine, and nanotechnology. Biosensors- devices that convert biological responses into quantifiable signals-have undergone significant advancements through innovations in nanotechnology, biochemistry, and engineering. These developments have improved their sensitivity and specificity for detecting cancer biomarkers, making them essential not only for early diagnosis but also for guiding personalized treatment strategies and ultimately improving patient outcomes. This review provides a comprehensive overview of biosensors, beginning with their historical development and fundamental principles, including mechanisms and key components. Various biosensor types, such as electrochemical, optical, mass-based, piezoelectric, thermal, magnetic, and plasmonic sensors, are discussed in detail, highlighting their roles in cancer detection. The integration of biomarkers into biosensing for cancer diagnostics and theranostic applications is examined, with emphasis on recent advancements in transdermal and imaging-based biosensors. Additionally, the challenges associated with biosensor technology-including sensitivity, specificity, reproducibility, and clinical translation-are addressed. The review concludes with future perspectives, focusing on innovations such as AI-driven biosensing, nanomaterial-based enhancements, and the potential for personalized cancer diagnostics. Overall, this work aims to provide a holistic understanding of biosensor applications in oncology while identifying key areas for further research and development.
Indexed as
Identifiers
41582576What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.